<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03979456</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2018-000721-31</org_study_id>
    <nct_id>NCT03979456</nct_id>
  </id_info>
  <brief_title>RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS</brief_title>
  <acronym>RIDOSE-MS</acronym>
  <official_title>RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS. A Randomized Trial of Long-term Dosage of Rituximab in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized trial of long-term dosage of rituximab in multiple sclerosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized phase 3 study comparing two dosing regimens of Rituximab in&#xD;
      long-term treatment of MS. Primary endpoint is no evidence of disease activity (NEDA) in a&#xD;
      non-inferiority analysis between 12-months dosing interval of 500 mg rituximab with 6-months&#xD;
      dosing interval. The endpoint is a compound of being free from release, new or enlarging MRI&#xD;
      lesions and sustained progression of disability measured by EDSS.&#xD;
&#xD;
      Each patient will have one treating physician responsible for all ongoing medical questions&#xD;
      and decisions regarding continuation in the study and one examining physician performing the&#xD;
      blinded Expanded Disability Status Scale examination and assessments of exacerbations. The&#xD;
      coordinating nurse will administer the study-related tests and administer the rituximab&#xD;
      infusions. MRI investigations will be performed blinded for the dosing arm allocation.&#xD;
&#xD;
      Randomization will be performed via a randomization module in the national Swedish MS&#xD;
      registry. The patients will be randomized in a 1:1 ratio and receive their treatments in&#xD;
      accordance with clinical practice. Thus, the study will mimic the real-life situation in&#xD;
      which the treatments will be administered. This will lead to a high degree of validity in&#xD;
      relation to expected outcome in clinical practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 4, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No evidence of disease activity (NEDA)</measure>
    <time_frame>3 years</time_frame>
    <description>The proportion of patients maintaining No Evidence of Disease Activity-3 (NEDA-3) during year 2 - 4 of the trial: No relapse, no new T2 lesions (&gt; 3 mm), no EDSS progression in either dose arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>No evidence of disease activity (NEDA) in subgroups</measure>
    <time_frame>4 years</time_frame>
    <description>The proportion of patients maintaining NEDA-3 comparing the previous rituximab arm with the previous DMF arm from the RIFUND trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first relapse</measure>
    <time_frame>3 yeas</time_frame>
    <description>Time to first relapse for the two dose arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom of new or enlarged lesions on MRI</measure>
    <time_frame>3 years</time_frame>
    <description>Proportion of patients in each dosing arm without new/enlarging T2 lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of brain atrophy</measure>
    <time_frame>3 years</time_frame>
    <description>Evolution of brain atrophy measured as brain parenchymal fraction (BPF) and corpus callosum area or -volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of confirmed sustained disability</measure>
    <time_frame>3 years</time_frame>
    <description>Proportion of patient with confirmed progression in EDSS according to pre-specified criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean progression of disability</measure>
    <time_frame>3 years</time_frame>
    <description>The mean change in EDSS over the trial period in the two dosing arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodegeneration</measure>
    <time_frame>3 years</time_frame>
    <description>The mean change of s-NFL concentration between the two dosing arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose persistence</measure>
    <time_frame>3 years</time_frame>
    <description>Time to discontinuation of dosing regimen allocation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of hypogammaglobulinaemia</measure>
    <time_frame>3 years</time_frame>
    <description>The occurrence of hypogammaglobulinaemia in the two dosing arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of neutropenia</measure>
    <time_frame>3 years</time_frame>
    <description>The occurrence of neutropenia in the two dosing arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of infections</measure>
    <time_frame>3 years</time_frame>
    <description>The occurrence of infections in the two dosing arms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health economy</measure>
    <time_frame>3 years</time_frame>
    <description>Estimation of societal costs per year to supply the two dosing arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment Satisfaction Questionnaire</measure>
    <time_frame>3 years</time_frame>
    <description>Validated scale that evaluate the degree of treatment satisfaction through 10 5- or 7 grade likert-scale questions</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>6-month dosing interval</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm is receiving standard dose rituximab 500 mg every 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12-month dosing interval</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm is receiving the comparator dose rituximab 500 mg every 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>After one year in the trial, the patients are split in the two dosing-arms described above. The dose-comparison phase continues four years.</description>
    <arm_group_label>12-month dosing interval</arm_group_label>
    <arm_group_label>6-month dosing interval</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Diagnosis of Relapsing Remitting MS according to the 2017 revised McDonald criteria OR&#xD;
             one demyelinating episode in conjunction with at least one asymptomatic high intensity&#xD;
             T2 lesion with size and location compatible with MS&#xD;
&#xD;
          -  The patient has completed the RIFUND-MS trial and is treated with either of the study&#xD;
             medications rituximab or DMF at the last visit of the RIFUND trial OR has been treated&#xD;
             with rituximab with a dose regimen of 500 - 1000 mg followed by 500 mg every 6 months&#xD;
             for up to two years as part of clinical practice&#xD;
&#xD;
          -  Age 20 - 52 years (inclusive)&#xD;
&#xD;
          -  EDSS 0 - 5,5 (inclusive)&#xD;
&#xD;
          -  The patient is willing and able to give written informed consent, according to the&#xD;
             judgement of the investigator.&#xD;
&#xD;
          -  In fertile females, willing to comply with effective contraceptive methods. These&#xD;
             include birth control pills, surgical sterilization of patient or partner or&#xD;
             intrauterine device. Non-fertile women is defined as more than 12 months of amenorrhea&#xD;
             without an alternative medical cause or, in case of ambiguities, an FSH level in the&#xD;
             postmenopausal range.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Diagnosis of Progressive MS&#xD;
&#xD;
          -  Previous treatment with any &quot;second-line&quot; immunomodulatory drug, eg natalizumab,&#xD;
             alemtuzumab, fingolimod, or other long-acting immunosuppressive agents.&#xD;
&#xD;
          -  Pregnant or lactating women s-HCG will be tested on all women at screening, before&#xD;
             each study-related infu-sion and in any situation where there is a reason to suspect&#xD;
             pregnancy during the trial, e.g delayed menstrual period more than five days above&#xD;
             expected time.&#xD;
&#xD;
          -  Patients having contraindication for or otherwise not compliant with MRI&#xD;
             investigations&#xD;
&#xD;
          -  Simultaneous treatment with other immunosuppressive drugs&#xD;
&#xD;
          -  Active, severe infections Signs of infections are assessed before inclusion and each&#xD;
             study-related infusion through clinical examination and further evaluated by&#xD;
             laboratory and other relevant investigations in case of suspected ongoing infection.&#xD;
             Hepatitis serology (HBsAg and anti-HBc) will be evaluated before treatment onset if&#xD;
             not tested within the previous three years.&#xD;
&#xD;
          -  Severe cardiac disorder, e.g signs of congestive heart failure or coronary artery&#xD;
             disease. This will be evaluated through clinical assessment before inclusion.&#xD;
&#xD;
          -  Vaccination within 4 weeks of first dose of study medication.&#xD;
&#xD;
          -  Documented allergy or intolerance to the IP&#xD;
&#xD;
          -  Severe psychiatric condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>52 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anders Svenningsson, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anders Svenningsson</name>
      <address>
        <city>Danderyd</city>
        <state>Stockholm</state>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Älvsborg Hospital</name>
      <address>
        <city>Borås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Falun Hospital</name>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gävle Hospital</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saghlgrenska Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsingborg Hospital</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karlstad Hospital</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Halland Hospital Kungsbacka</name>
      <address>
        <city>Kungsbacka</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyköping Hospital</name>
      <address>
        <city>Nyköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capio StGöran Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fredrik Piehl</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Hospital Huddinge</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umeå University</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala Academiska Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Östersund Hospital</name>
      <address>
        <city>Östersund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Anders Svenningsson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Relapsing-Remitting</keyword>
  <keyword>Dosing protocols</keyword>
  <keyword>Randomized trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

